Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Kathy Dominy, Matthew Salmon, Richard Szydlo, Chloe Hayden, Helen E White, Mary Alikian, Dragana Milojkovic, Mhairi Copland, Letizia Foroni, Nicholas C.P. Cross, Richard E Clark, Jane F. Apperley

Blood (2022) 140 (Supplement 1): 9631–9632.

https://doi.org/10.1182/blood-2022-170375

Published: 2022

Journal Articles

Real-World Experience of Asciminib: Factors Associated with Response

Blood (2022) 140 (Supplement 1): 6796–6797.

https://doi.org/10.1182/blood-2022-165501

Published: 2022

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider, Lone Bredo Pedersen, Renee C. Tschumper, Lesley-Ann Sutton, Panagiotis Baliakas, Lydia Scarfò, Ellen J. van Gastel, Marine Armand, Eugen Tausch, Bella Biderman, Constance Baer, Davide Bagnara, Alba Navarro, Anne Langlois de Septenville, Valentina Guido, Gerlinde Mitterbauer-Hohendanner, Aleksandar Dimovski, Christian Brieghel, Sarah Lawless, Manja Meggendorfer, Kamila Brazdilova, Matthias Ritgen, Monica Facco, Cristina Tresoldi, Andrea Visentin, Andrea Patriarca, Mark Catherwood, Lisa Bonello, Andrey Sudarikov, Katrina Vanura, Maria Roumelioti, Hana Skuhrova Francova, Theodoros Moysiadis, Silvio Veronese, Krzysztof Giannopoulos, Larry Mansouri, Teodora Karan-Djurasevic, Raphael Sandaltzopoulos, Csaba Bödör, Franco Fais, Arnon Kater, Irina Panovska, Davide Rossi, Salem Alshemmari, Panagiotis Panagiotidis, Paul Costeas, Blanca Espinet, Darko Antic, Letizia Foroni, Marco Montillo, Livio Trentin, Niki Stavroyianni, Gianluca Gaidano, Paola Francia di Celle, Carsten Niemann, Elias Campo, Achilles Anagnostopoulos, Christiane Pott, Kirsten Fischer, Michael Hallek, David Oscier, Stephan Stilgenbauer, Claudia Haferlach, Diane Jelinek, Nicholas Chiorazzi, Sarka Pospisilova, Marie-Paule Lefranc, Sofia Kossida, Anton W. Langerak, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 137 (10): 1365–1376.

https://doi.org/10.1182/blood.2020007039

Published: 2021

Includes: Supplemental data

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD

Blood (2018) 132 (Supplement 1): 457.

https://doi.org/10.1182/blood-2018-99-110128

Published: 2018

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Simone Claudiani, MD, Jane Apperley, MB ChB MD, Afzal Khan, Richard Szydlo, PhD, George Nesr, MD, George Adams, MBChB, Letizia Foroni, MD PhD, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2018-99-119602

Published: 2018

Journal Articles

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

Louise Caldwell, BSc, Simone Claudiani, MD, Dragana Milojkovic, MBBS, PhD, Richard Szydlo, PhD, Elisabetta Abruzzese, MD, George Nesr, MD, Michael J. Mauro, MD, Renuka Palanicawander, MD, Aoife Gatenby, BSc, Ira Sabli, BSc, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1612.

https://doi.org/10.1182/blood.V130.Suppl_1.1612.1612

Published: 2017

Journal Articles

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Simone Claudiani, MD, Adi Shacham Abulafia, Ira Sabli, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1628.

https://doi.org/10.1182/blood.V130.Suppl_1.1628.1628

Published: 2017

Journal Articles

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Simone Claudiani, MD, Aoife Gatenby, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, Emily Ching, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1629.

https://doi.org/10.1182/blood.V130.Suppl_1.1629.1629

Published: 2017

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Mary Alikian, MSc, PhD, Alexandra S. Whale, Simon Cowen, Kim Piechocki, Michael John Griffiths, BSc, Alistair G Reid, BSc, PhD, Susanna Akiki, Jane F. Apperley, MD, Jim F. Huggett, Letizia Foroni

Blood (2016) 128 (22): 3104.

https://doi.org/10.1182/blood.V128.22.3104.3104

Published: 2016

Journal Articles

Germline Calr exon 9 Variant and Somatic JAK2 V617F Mutation in a Patient with Polycythemia Vera Associated with Late Presentation and Severe Clinical Phenotype

Chieh Lee Wong, Gareth Gerrard, Zainul Abidin Norziha, Nor Rafeah Tumian, Soon Keng Cheong, Chooi Fun Leong, Ping Chong Bee, Jameela Sathar, Liming Liang, Tim Aitman, Letizia Foroni, Michael Laffan

Blood (2016) 128 (22): 5485.

https://doi.org/10.1182/blood.V128.22.5485.5485

Published: 2016

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

Differential Expression of Genes Associated with Oncogene-Induced Senescence and Senescence Associated Secretory Phenotype in the Absence of Differential Expression of High Molecular Risk Genes and Genes Associated with JAK-STAT Pathway in Sorted Cells of Patients with Polycythemia Vera and Primary Myelofibrosis

Chieh Lee Wong, Andrew Innes, Baoshan Ma, Gareth Gerrard, Zainul Abidin Norziha, Soon Keng Cheong, Chooi Fun Leong, Ping Chong Bee, Jameela Sathar, Siew Fen Lye, Letizia Foroni, Tim Aitman, Liming Liang, Jesus Gil, Michael Laffan

Blood (2016) 128 (22): 4283.

https://doi.org/10.1182/blood.V128.22.4283.4283

Published: 2016

Journal Articles

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Simone Claudiani, Nikhita Gupta, BSc, Ji Soo Baik, BSc, Simona Deplano, MDPhD, Renuka Palanicawander, Gareth Gerrard, Alistair G Reid, BSc, PhD, Richard M Szydlo, BSc, PhD, Dragana Milojkovic, Letizia Foroni, Jane F. Apperley, MD

Blood (2015) 126 (23): 2794.

https://doi.org/10.1182/blood.V126.23.2794.2794

Published: 2015

Journal Articles

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Jeeyune Bahk, BSc, Simone Claudiani, MD, Richard M Szydlo, BSc, PhD, Sarmad Toma, BSc, Faisal Abdillah, BSc, Sandra Hing, BSc, Simona Deplano, MDPhD, Dragana Milojkovic, Jane F Apperley, MD, Letizia Foroni, MD PhD

Blood (2015) 126 (23): 2795.

https://doi.org/10.1182/blood.V126.23.2795.2795

Published: 2015

Journal Articles

Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences

Jacqueline Dickson, PhD, Nick Kennedy, MBBS MA Cantab FRACP, Leanne M. Cork, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Corinne A. Hedgley, BSc (Hons), Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Tessa L. Holyoake, MDPhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Bernard Ramashoye, PhDMRCP FRCPath

Blood (2015) 126 (23): 4021.

https://doi.org/10.1182/blood.V126.23.4021.4021

Published: 2015

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

NARROW

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Real-World Experience of Asciminib: Factors Associated with Response

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Germline Calr exon 9 Variant and Somatic JAK2 V617F Mutation in a Patient with Polycythemia Vera Associated with Late Presentation and Severe Clinical Phenotype

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only